allakos.com valuation and analysis

Robots.txt Information
Robot Path Permission
GoogleBot /
BingBot /
BaiduSpider /
YandexBot /
User-agent: * Disallow: Crawl-delay:
Meta Tags
Title Allakos │ Therapeutic antibodies │ Mast cells and
Description Allakos is developing therapeutic antibodies that selectively target eosinophils and mast cells, cells that play a significant role in many
Keywords N/A
Server Information
WebSite allakos faviconallakos.com
Host IP 69.63.140.80
Location United States
Related Websites
Site Rank
More to Explore
allamericanmodularllc.com
americanoldtimercars.com
amorousaccessories.com
annhiatt.co
annie-louise.com
anotherjo.com
anureads.com
apawsitiveapproach.com
apetrifiedforest.com
apollon7group.com
appcity.com
appliedlng.com
aquariumdesignpro.com
arcadiamanagementllc.com
aristabeads.com
aroirestaurant.com
aromaindianbistro.com
arsoi.com
artipiagames.gr
artisticoutdoors.com
allakos.com Valuation
US$32,879,390
Last updated: 2023-05-10 09:01:26

allakos.com has Semrush global rank of 321,913. allakos.com has an estimated worth of US$ 32,879,390, based on its estimated Ads revenue. allakos.com receives approximately 3,793,776 unique visitors each day. Its web server is located in United States, with IP address 69.63.140.80. According to SiteAdvisor, allakos.com is safe to visit.

Traffic & Worth Estimates
Purchase/Sale Value US$32,879,390
Daily Ads Revenue US$30,351
Monthly Ads Revenue US$910,507
Yearly Ads Revenue US$10,926,075
Daily Unique Visitors 252,919
Note: All traffic and earnings values are estimates.
DNS Records
Host Type TTL Data
allakos.com. A 14399 IP: 69.63.140.80
allakos.com. NS 3600 NS Record: ns34.domaincontrol.com.
allakos.com. NS 3600 NS Record: ns33.domaincontrol.com.
allakos.com. MX 3600 MX Record: 0 allakos-com.mail.protection.outlook.com.
allakos.com. TXT 3600 TXT Record: docusign=899ed47f-5976-40e8-8e90-1f138ad904d5
allakos.com. TXT 3600 TXT Record: adobe-idp-site-verification=ee3c55b0528626a918fb314886d99e5ee7612955835a28187df4369e1cbf4035
allakos.com. TXT 3600 TXT Record: apple-domain-verification=VnEjL2m4KDNUHWju
allakos.com. TXT 3600 TXT Record: MS=ms48889298
allakos.com. TXT 3600 TXT Record: docusign=bf966157-e1f6-4710-bc26-2da49e09905b
allakos.com. TXT 3600 TXT Record: ivdm84f266ohao15djmmdmse1s
allakos.com. TXT 3600 TXT Record: v=spf1 ip4:50.237.164.158 ip4:12.48.67.66 ip4:44.229.49.190 ip4:104.129.192.94 ip4:54.212.92.75 include:spf.protection.outlook.com include:email.freshservice.com include:emailus.freshservice.com include:prtg.com ~all
HtmlToTextCheckTime:2023-05-10 09:01:26
Developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases Novel Biology developing therapeutic antibodies targeting Siglec receptors Lead Programs Focused on Inhibiting Mast Cell and/or Eosinophil Activation mast cells and eosinophils are pathogenic in a number of inflammatory diseases Lirentelimab (AK002) an investigational monoclonal antibody that depletes eosinophils and inhibits mast cells AK006 an investigational monoclonal antibody that selectively and potently inhibits mast cells, including KIT mediated signaling Multiple Indications within Inflammation & Immunology: Conducting Phase 2 studies in Chronic Spontaneous Urticaria and Atopic Dermatitis About Overview Management Board of Directors Scientific Advisors Science Overview Biology Lirentelimab (AK002) AK006 AK007 Scientific Presentations Clinical Overview Chronic Spontaneous Urticaria Atopic Dermatitis Patients Allakos
HTTP Headers
HTTP/1.1 301 Moved Permanently
Date: Tue, 02 Nov 2021 12:21:28 GMT
Server: Apache
Location: https://www.allakos.com/
Content-Type: text/html; charset=iso-8859-1

HTTP/1.1 200 OK
Date: Tue, 02 Nov 2021 12:21:28 GMT
Server: Apache
Vary: User-Agent,Accept-Encoding
Last-Modified: Tue, 26 Oct 2021 15:08:43 GMT
Cache-Control: max-age=30, s-maxage=30
Expires: Tue, 02 Nov 2021 12:21:58 GMT
X-Frame-Options: SAMEORIGIN
X-Content-Type-Options: nosniff
X-XSS-Protection: 1; mode=block
Strict-Transport-Security-Test: max-age=60
Content-Security-Policy-Report-Only:  default-src 'self' data:; report-uri /csp.cfm; style-src 'self' 'unsafe-inline' fonts.googleapis.com *.typekit.net; font-src 'self' data: https:; frame-ancestors 'self'; frame-src 'self' player.vimeo.com *.youtube.com www.google.com https://recruitingbypaycor.com; script-src 'self' 'unsafe-eval' 'unsafe-inline' ajax.googleapis.com www.google-analytics.com www.googletagmanager.com https://recruitingbypaycor.com https://newton.newtonsoftware.com; img-src 'self' data: www.google-analytics.com https://*.vimeocdn.com www.googletagmanager.com; connect-src 'self' www.google-analytics.com
Content-Type: text/html;charset=UTF-8
allakos.com Whois Information
Domain Name: ALLAKOS.COM
Registry Domain ID: 1719008346_DOMAIN_COM-VRSN
Registrar WHOIS Server: whois.godaddy.com
Registrar URL: http://www.godaddy.com
Updated Date: 2019-12-13T22:38:03Z
Creation Date: 2012-05-08T21:12:27Z
Registry Expiry Date: 2028-05-08T21:12:27Z
Registrar: GoDaddy.com, LLC
Registrar IANA ID: 146
Registrar Abuse Contact Email: abuse@godaddy.com
Registrar Abuse Contact Phone: 480-624-2505
Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited
Domain Status: clientRenewProhibited https://icann.org/epp#clientRenewProhibited
Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited
Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited
Name Server: NS33.DOMAINCONTROL.COM
Name Server: NS34.DOMAINCONTROL.COM
DNSSEC: unsigned
>>> Last update of whois database: 2021-09-20T19:58:52Z <<<